Literature DB >> 10423250

Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand.

T Crass1, W Bautsch, S A Cain, J E Pease, P N Monk.   

Abstract

Despite the expression of only one type of receptor, there is great variation in the ability of different cell types to discriminate between C5a and its more stable metabolite, C5a des Arg74. The mechanism that underlies this phenomenon is not understood but presumably involves differences in the interaction with the C5a receptor. In this paper, we have analyzed the effects of a substitution mutation of the receptor (Glu199 --> Lys199) and the corresponding reciprocal mutants (Lys68 --> Glu68) of C5a, C5a des Arg74 and peptide analogues of the C-terminus of C5a on the ability of the C5a receptor to discriminate between ligands with and without Arg74. The use of these mutants indicates that the Lys68/Glu199 interaction is essential for activation of receptor by C5a des Arg74 but not for activation by intact C5a. The substitution of Asp for Arg74 of C5a [Lys68] produces a ligand with equal potency on both the wild-type and mutant receptors, suggesting that it is the C-terminal carboxyl group rather than the side chain of Arg74 that controls the responsiveness of the receptor to Lys68. In contrast, the mutation of Lys68 to Glu(68) has little effect on the ability of either C5a or C5a des Arg(74) to displace [(125)I]C5a from the receptors, indicating that binding of ligand and receptor activation are distinct but interdependent events. C5a and the truncated ligand, C5a des Arg74, appear to have different modes of interaction with the receptor and the ability of the human C5a receptor to discriminate between these ligands is at least partly dependent on an interaction with the receptor residue, Glu199.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423250     DOI: 10.1021/bi990139q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss.

Authors:  Shuang Liang; Jennifer L Krauss; Hisanori Domon; Megan L McIntosh; Kavita B Hosur; Hongchang Qu; Fenge Li; Apostolia Tzekou; John D Lambris; George Hajishengallis
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

2.  C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay.

Authors:  Edimara S Reis; Hui Chen; Georgia Sfyroera; Peter N Monk; Jörg Köhl; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2012-10-05       Impact factor: 5.422

Review 3.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

4.  Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response.

Authors:  Andrew J Wright; Adrian Higginbottom; Didier Philippe; Abhishek Upadhyay; Stefan Bagby; Robert C Read; Peter N Monk; Lynda J Partridge
Journal:  Mol Immunol       Date:  2007-01-26       Impact factor: 4.407

5.  A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling.

Authors:  Reena Halai; Daniel E Croker; Jacky Y Suen; David P Fairlie; Matthew A Cooper
Journal:  Biosensors (Basel)       Date:  2012-07-26

6.  Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.

Authors:  Soumendra Rana; Amita Rani Sahoo
Journal:  Biochem Biophys Rep       Date:  2015-03-24

7.  Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways.

Authors:  Ling-Ling An; Jacob V Gorman; Geoffrey Stephens; Bonnie Swerdlow; Paul Warrener; Jessica Bonnell; Tomas Mustelin; Michael Fung; Roland Kolbeck
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.